公开(公告)号：US20230000966A1

公开(公告)日：2023-01-05

申请号：US17772610

申请日：2020-10-28

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Ye Che ,  Wei Chen ,  Laurent Oliver Chorro ,  Ling Chu ,  Robert G.K. Donald ,  Matthew Curtis Griffor ,  Jianxin Gu ,  Zeqiang Guan ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Scott Ellis Lomberk ,  Jason Arnold Lotvin ,  Nishith Merchant ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  David Robert Stead ,  Karen Kiyoko Takane

IPC: A61K39/108 ,  C07K14/245

Abstract: In one aspect, the invention relates to a polypeptide derived from E. coli and a fragment thereof, including compositions and methods thereof. Also disclosed herein are compositions that include a polypeptide derived from E. coli and a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. In a further aspect, disclosed herein are mammalian host cells that include sequence(s) encoding a polypeptide derived from E. coli or fragments thereof.

公开(公告)号：US20220387613A1

公开(公告)日：2022-12-08

申请号：US17824293

申请日：2022-05-25

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Caitlyn Gallagher ,  Jianxin Gu ,  Isis Kanevsky ,  Jin-Hwan Kim ,  Justin Keith Moran ,  Suddham Singh ,  Naveen Surendran

IPC: A61K47/64 ,  A61K39/09 ,  A61P31/04

Abstract: The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.

公开(公告)号：US11260119B2

公开(公告)日：2022-03-01

申请号：US16534457

申请日：2019-08-07

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  C08B37/00 ,  A61P31/04 ,  A61P37/04 ,  A61K39/00

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

公开(公告)号：US20240350608A1

公开(公告)日：2024-10-24

申请号：US18634326

申请日：2024-04-12

Applicant: Pfizer Inc.

Inventor： Bishwa Raj Bhetuwal ,  Kaushik Dutta ,  Jianxin Gu ,  Sunayana Kapil ,  Jin-Hwan Kim ,  Justin Keith Moran ,  Suddham Singh ,  YuYing Yang

IPC: A61K39/09 ,  A61K39/00 ,  A61K39/385 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/646 ,  A61K39/385 ,  A61K2039/55516

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

公开(公告)号：US20240325515A1

公开(公告)日：2024-10-03

申请号：US18621962

申请日：2024-03-29

Applicant: Pfizer Inc.

Inventor： Kaushik Dutta ,  Caitlyn Gallagher ,  Isis Kanevsky ,  Jin-hwan Kim ,  Justin Keith Moran ,  Suddham Singh ,  Abhishek Ravindra Vartak

IPC: A61K39/09 ,  A61K39/00 ,  A61K47/42 ,  A61P31/04

CPC classification number: A61K39/092 ,  A61K47/42 ,  A61P31/04 ,  A61K2039/55505

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

公开(公告)号：US20200061177A1

公开(公告)日：2020-02-27

申请号：US16534457

申请日：2019-08-07

Applicant: Pfizer Inc.

Inventor： Robert G.K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  C08B37/00 ,  A61P37/04 ,  A61P31/04

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

公开(公告)号：US10226525B2

公开(公告)日：2019-03-12

申请号：US15144884

申请日：2016-05-03

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G. K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/00 ,  C07K16/12 ,  C07K16/44 ,  A61K39/40 ,  A61K39/09 ,  A61K39/39 ,  A61K47/10 ,  A61K47/26

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.